CTRI/2009/091/000641CompletedPhase 1
A prospective open-label single-arm multi-centric clinical study to assess the safety and efficacy of ReliNethra C-Au (Autologous Conjunctival epithelial cell graft) in patients with pterygium
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Male or female patients of 18 years and above
- •2. Patients with damaged or diseased conjunctival surface requiring surgical correction of pterygium, symblepharon, chronic allergic conjunctivitis, toxic epidermal necrolysis, wide field excision of tumors, and/or chemical injuries (as confirmed by history, prior medical records and/or clinical examination)
Exclusion Criteria
- •1. History of significant hematological, hepatic, renal, cardiovascular, respiratory, neurological, endocrinal or allergic disease
- •2. Patient with documented HIV infection/AIDS
- •3. Patients with history of diabetes
- •4. Patients with any ocular surface abnormality in the other eye
Investigators
Similar Trials
Completed
Phase 4
A prospective single-centre single-arm open-label study of the long-term use of a LHRH agonist (Decapeptyl SR 11.25mg) in combination with livial add-back therapy in the management of chronic cyclical pelvic pain in pre-menopausal womeTopic: Reproductive Health and ChildbirthSubtopic: Reproductive Health and Childbirth (all Subtopics)Disease: Reproductive Health & ChildbirthSigns and SymptomsAbdominal and pelvic painISRCTN19040577Sheffield Teaching Hospitals NHS Trust (UK)31
Recruiting
Not Applicable
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B (ADAPT)KCT0005929Asan Medical Center140
Completed
Phase 4
The primary purpose of this study is to evaluate the post-marketingsafety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) underactual conditions of use, and to understand the incidence ofadverse events (AEs) (serious and non-serious AEs).CTRI/2019/04/018710Johnson and Johnson Private Limited75
Completed
Phase 4
Effectiveness of Restylane® used for treatment of facial wrinkles, facial folds, volume loss and lips augmentation.CTRI/2017/09/009848Galderma India Pvt Ltd100
Active, not recruiting
Phase 4
A study to evaluate the safety and efficacy of Nutricharge Glycem Tablet administered with Nutricharge Glycem Prodiet in Pre-diabetic subjectsCTRI/2017/10/010007Trophic Wellness Private Limited